CLSI. 2022. Performance Standards for Antimicrobial Susceptibility Testing, M100 32nd Edition. Clinical and Laboratory Standards Institute, Wayne, PA. Harris et al. 2018. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli ...
Susceptibilities of aminoglycoside were assessed based on previous breakpoints in CLSI M100-S32 in 2022 as well as the current breakpoints from the most recent CLSI MIC breakpoints in 2023. RESULTS. We evaluated 1,393 CRE isolates. Most isolates were Klebsiella pneumoniae [n=876 (62.9%)] and ...
While the focus was the change of piperacillin / tazobactam (TZP) BP in Enterobacterales in 2022 [2], CLSI M100-Ed33, released this year has brought numerous changes and made AST reporting more objective with inclusion of selective and cascade reporting protocols [2,3]....